"2"^^ . "1"^^ . "Pacienti s karcinomy \u0161t\u00EDtn\u00E9 \u017El\u00E1zy jsou standardn\u011B l\u00E9\u010Deni tot\u00E1ln\u00ED tyroidektomi\u00ED a n\u00E1slednou eliminac\u00ED zbytk\u016F \u0161t\u00EDtn\u00E9 \u017El\u00E1zy radioaktivn\u00EDm j\u00F3dem 131; pot\u00E9 jsou l\u00E9\u010Deni levotyroxinem s c\u00EDlem suprimovat tyreotropin. V n\u011Bkolika t\u00FDdnech tak z hypotyre\u00F3zy p\u0159ejdou do subklinick\u00E9 hypertyre\u00F3zy, kter\u00E1 se pak udr\u017Euje dlouhodob\u011B, n\u011Bkdy celo\u017Eivotn\u011B. Pon\u011Bkud kontroverzn\u00ED liter\u00E1rn\u00ED data ukazuj\u00ED, \u017Ee hypotyre\u00F3za b\u00FDv\u00E1 \u010Dast\u011Bji spojen\u00E1 s vy\u0161\u0161\u00EDm rizikem krv\u00E1cen\u00ED a hypertyre\u00F3za s vy\u0161\u0161\u00EDm rizikem tromb\u00F3zy; to se m\u016F\u017Ee pod\u00EDlet na zv\u00FD\u0161en\u00E9 mortalit\u011B pacient\u016F s hypertyre\u00F3zou, i subklinickou. V uveden\u00E9 modelov\u00E9 situaci rychl\u00E9 zm\u011Bny z hypotyre\u00F3zy do subklinick\u00E9 hypertyre\u00F3zy pl\u00E1nujeme vy\u0161et\u0159it, v p\u00E1rov\u00E9m uspo\u0159\u00E1d\u00E1n\u00ED, vybran\u00E9 parametry prim\u00E1rn\u00ED hemost\u00E1zy, hemokoagulace a fibrinol\u00FDzy, pop\u0159. i endoteli\u00E1ln\u00ED dysfunkce. O\u010Dek\u00E1v\u00E1me, \u017Ee v\u00FDsledky umo\u017En\u00ED posoudit hemostaticko/hemokoagula\u010Dn\u00ED rizika standardn\u00ED l\u00E9\u010Dby karcinom\u016F \u0161t\u00EDtn\u00E9 \u017El\u00E1zy a z\u00E1rove\u0148 oz\u0159ejmit, kter\u00E1 oblast v hemokoagula\u010Dn\u00ED rovnov\u00E1ze je c\u00EDlov\u00FDm m\u00EDstem \u00FA\u010Dinku tyroid\u00E1ln\u00EDch hormon\u016F." . "NT13535" . . "http://www.isvav.cz/projectDetail.do?rowId=NT13535"^^ . . . . "thyroid cancer; thyroid hormones; haemostasis; haemocoagulation; fibrinolysis; endothelial dysfunction"@en . . . . "2014-12-31+01:00"^^ . . . "2013-03-26+01:00"^^ . " fibrinolysis" . . "2012-04-01+02:00"^^ . . " thyroid hormones" . . "2015-01-22+01:00"^^ . "Thyroid cancer patients are routinely treated by total thyroidectomy followed by radioiodine ablation of the remnants; thereafter they receive levothyroxine with the aim to suppress their thyrotropin level. Within several weeks they shift from severe hypothyroidism to mild hyperthyroidism; it is then kept for several years, and sometimes life-long. Partially controversial literary data suggest that hypothyroidism may be accompanied by a risk of bleeding, while hyperthyroidism may be prothrombotic, possibly related to an increased mortality of even mildly hyperthyroid patients. In the above mentioned setting of a rapid shift from hypothyroidism to mild hyperthyroidism, we plan to perform (in paired design) several tests related to primary haemostasis, haemocoagulation, and fibrinolysis. It may help us to assess the risks of bleeding and thrombosis related to the standard thyroid cancer treatment, and to improve our understanding of mode of action of thyroid hormones in haemostasis."@en . . . . "0"^^ . "Vztah hormon\u016F \u0161t\u00EDtn\u00E9 \u017El\u00E1zy k hemost\u00E1ze a hemokoagulaci u pacient\u016F s karcinomy \u0161t\u00EDtn\u00E9 \u017El\u00E1zy" . "The relationship of thyroid hormones to haemostasis and haemocoagulation in thyroid cancer patients"@en . . "thyroid cancer" . "0"^^ . " haemostasis" . " haemocoagulation" . . "2"^^ .